PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30117016-0	2018	miR-129-5p inhibits gemcitabine resistance and promotes cell apoptosis of bladder cancer cells by targeting Wnt5a.	gemcitabine	20-31	microRNA 1295a	Homo sapiens	0-10	
30117016-2	2018	This study was aimed to investigate the potential role of miR-129-5p in the development of gemcitabine resistance in bladder cancer cells and its underlying mechanism.	gemcitabine	91-102	microRNA 1295a	Homo sapiens	58-68	
30117016-7	2018	RESULTS: We found that down-regulated miR-129-5p level contributed to gemcitabine resistance in bladder cancer cells and tissues.	gemcitabine	70-81	microRNA 1295a	Homo sapiens	38-48	
30117016-8	2018	We also observed restoration of miR-129-5p could significantly increase cell sensitivity to gemcitabine and promote cell apoptosis.	gemcitabine	92-103	microRNA 1295a	Homo sapiens	32-41	
30117016-9	2018	Mechanism analysis revealed that Wnt5a is a direct target gene of miR-129-5p and knock-down of Wnt5a reversed gemcitabine resistance.	gemcitabine	110-121	Wnt family member 5A	Homo sapiens	33-38	
30117016-9	2018	Mechanism analysis revealed that Wnt5a is a direct target gene of miR-129-5p and knock-down of Wnt5a reversed gemcitabine resistance.	gemcitabine	110-121	microRNA 1295a	Homo sapiens	66-76	
30117016-9	2018	Mechanism analysis revealed that Wnt5a is a direct target gene of miR-129-5p and knock-down of Wnt5a reversed gemcitabine resistance.	gemcitabine	110-121	Wnt family member 5A	Homo sapiens	95-100	
30117016-10	2018	CONCLUSIONS: Taken together, our findings indicate that miR-129-5p and Wnt5a may be novel therapeutic targets for overcoming gemcitabine resistance in bladder cancer treatment.	gemcitabine	125-136	microRNA 1295a	Homo sapiens	56-66	
30117016-10	2018	CONCLUSIONS: Taken together, our findings indicate that miR-129-5p and Wnt5a may be novel therapeutic targets for overcoming gemcitabine resistance in bladder cancer treatment.	gemcitabine	125-136	Wnt family member 5A	Homo sapiens	71-76